← Back to Clinical Trials
Recruiting NCT06224764

NCT06224764 Assessment of the Impact of the Return Home of Premature Newborns Less Than 2 Kilos Morbidity/Mortality

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06224764
Status Recruiting
Phase
Sponsor Hôpital NOVO
Condition Premature Birth
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2024-02-21
Primary Completion 2025-11

Eligibility & Interventions

Sex All sexes
Min Age 1 Month
Max Age 11 Years
Study Type INTERVENTIONAL
Interventions
Mother and Father questionnaires

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2024-02-21 with a primary completion date of 2025-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to evaluate the impact of discharge from hospital with a weight of less than 2 kilos. To do this, the investigator will look at the short-term and long-term outcome of newborns weighing less than 2 kilos who were discharged from the neonatology department at the NOVO hospital between 2012 and 2024.

Eligibility Criteria

Inclusion Criteria: * Premature newborn baby (born at less than 37 days' gestation) * Newborn baby with IUGR (Intra-Uterine Growth Retardation) * Newborn baby hospitalised in the neonatology department of the NOVO hospital - Pontoise site * Patient born between 01/01/2012 and 31/12/2024. * Newborn who has left the neonatology department or the Kangaroo Unit to return home weighing less than 2 kg. * Newborn beneficiary of a social security scheme or entitled person. Exclusion Criteria: * Newborn transferred to another hospital before discharge. * Refusal by one of the parents. * Parent does not speak or understand French.

Contact & Investigator

Central Contact

Maryline DELATTRE

✉ maryline.delattre@ght-novo.fr

📞 +3333130754131

Principal Investigator

Dr Suzanne BORRHOMEE

PRINCIPAL INVESTIGATOR

Hôpital NOVO

Frequently Asked Questions

Who can join the NCT06224764 clinical trial?

This trial is open to participants of all sexes, aged 1 Month or older, up to 11 Years, studying Premature Birth. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06224764 currently recruiting?

Yes, NCT06224764 is actively recruiting participants. Contact the research team at maryline.delattre@ght-novo.fr for enrollment information.

Where is the NCT06224764 trial being conducted?

This trial is being conducted at Pontoise, France.

Who is sponsoring the NCT06224764 clinical trial?

NCT06224764 is sponsored by Hôpital NOVO. The principal investigator is Dr Suzanne BORRHOMEE at Hôpital NOVO. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology